HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia

Files in This Item:
IJH94-3_291-295.pdf313.7 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/47958

Title: Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia
Authors: Arita, Kotaro Browse this author
Kondo, Takeshi Browse this author
Sugita, Junichi Browse this author
Shigematsu, Akio Browse this author
Shiratori, Souichi Browse this author
Wakasa, Kentaro Browse this author
Yasumoto, Atsushi Browse this author
Ibata, Makoto Browse this author
Shono, Yusuke Browse this author
Kikuchi, Misato Browse this author
Goto, Hideki Browse this author
Takeda, Yukari Browse this author
Takahata, Mutsumi Browse this author
Kato, Naoko Browse this author
Nishio, Mitsufumi Browse this author
Ota, Shuichi Browse this author
Tanaka, Junji Browse this author
Imamura, Masahiro Browse this author →KAKEN DB
Keywords: Acute lymphoblastic leukemia
Allogeneic hematopoietic stem cell transplantation
Non-CR
Refractory leukemia
Induction failure
Issue Date: Sep-2011
Publisher: Springer Japan
Journal Title: International Journal of Hematology
Volume: 94
Issue: 3
Start Page: 291
End Page: 295
Publisher DOI: 10.1007/s12185-011-0919-3
PMID: 21879292
Abstract: The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m2 for 3 days, VCR 1.4 mg/m2 for 1 day, and PSL 60 mg/m2 for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL.
Rights: The final publication is available at www.springerlink.com
Type: article (author version)
URI: http://hdl.handle.net/2115/47958
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 今村 雅寛

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University